Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Melanotan I and Oxytocin — mechanism, side effects, legal status, and pricing.
Melanotan I (Afamelanotide) is a synthetic analog of alpha-MSH that selectively activates MC1R. FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), it is distinct from Melanotan II and is studied for melanogenesis and photoprotection.
Oxytocin is a nine-amino acid peptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, with a disulfide bridge between Cys1 and Cys6) produced in the hypothalamic paraventricular and supraoptic nuclei. The synthetic form (Pitocin) is FDA-approved as IV/IM injection for labor induction/augmentation and postpartum hemorrhage control. Intranasal oxytocin is NOT FDA-approved and is used off-label or in research settings for social/behavioral indications, where evidence is mixed.
Melanotan I
Oxytocin
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Melanotan I
Oxytocin
COA corpus from Disclosed Labs — independently tested batches only.
Melanotan I
50
COAs
99.7%
Avg purity
12
Labs
Oxytocin
32
COAs
99.0%
Avg purity
9
Labs
FDA-approved as Scenesse (Clinuvel, October 8, 2019) for increasing pain-free light exposure in adults with EPP, based on Phase III trials CUV039 and CUV040 showing more hours spent in sunlight without pain vs. placebo (Langendonk et al., NEJM, 2015; PMID 26132941). A randomized multicenter trial (Lim et al., JAMA Dermatology, 2015; PMID 25230094) also showed increased repigmentation when afamelanotide was combined with narrow-band UVB in vitiligo.
Pitocin has decades of obstetric use under its FDA label. Intranasal oxytocin has been studied in dozens of RCTs across autism, social anxiety, PTSD, and schizophrenia. Evidence is MIXED and frequently negative for larger/more rigorous trials. Sikich et al. 2021 (NEJM, SOARS-B, PMID 34644471) — the largest placebo-controlled RCT (N=290) of intranasal oxytocin for autism — found no significant benefit over placebo on social or cognitive functioning over 24 weeks. Ooi et al. 2017 meta-analysis (PMID 27574858) found no significant overall effect of oxytocin on social cognition or repetitive behaviors in ASD. Leng & Ludwig 2016 'Intranasal Oxytocin: Myths and Delusions' (Biological Psychiatry, PMID 26049207) estimate <0.005% of intranasal dose reaches CSF, questioning the pharmacologic basis for reported behavioral effects. Marketing of intranasal oxytocin as a 'love/bonding' compound is not supported by the strongest clinical evidence. Pitocin FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf
Melanotan I (Cosmetic) and Oxytocin (Hormone) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs